Real world single center experience on the efficacy of stopping long term nucleos(t)ide analog therapy in patients with chronic hepatitis B
Stopping Anti-HBV NUCs “Feasible” if HBeAg-Negative and HBsAg Below 100 IU/mL
AASLD The Liver Meeting Digital Experience, November 13-16, 2020
Mark Mascolini
Stopping nucleos(t)ides (NUCs) for chronic HBV infection proved feasible and generally safe in people negative for HBeAg and with quantitative HBsAg (qHBsAg) below 100 IU/mL, according to results of a retrospective single-center study in Canada [1]. Six of 47 people (13%) who stopped NUCs had to restart because of virologic or biochemical flares.
University of Calgary researchers who conducted this study noted that NUC therapy for chronic HBV infection rarely leads to loss of hepatitis B surface antigen (HBsAg), which indicates current infection. As a result, therapy becomes prolonged for most people with chronic HBV. The Calgary team pointed out that some guidelines say hepatitis B e antigen (HBeAg)-positive people may stop NUCs after HBeAg seroconversion, undetectable HBV DNA for more than 6 to 12 months, and consolidation therapy [2], yet many relapse when NUCs stop. (HBeAg indicates ongoing HBV replication and the possibility of transmission.)
Because some evidence suggests NUCs can be stopped safely in HBV patients without cirrhosis, with undetectable HBV DNA, and with qHBsAg levels under 100 IU/mL, the Calgary researchers analyzed that approach in their long-term NUC patients, aiming to determine baseline factors that predicted off-treatment durability.
The analysis involved 1337 people taking long-term NUCs for chronic HBV infection. The researchers determined that 47 in this group (3.5%) stopped NUCs on their clinician’s advice. Fourteen of the 47 (30%) were women, 37 (78%) were East Asian, and median age stood at 56 years (range 18 to 74). While 28 people (60%) were taking tenofovir disoproxil fumarate (TDF), 16 (34%) took entecavir and 3 (6%) lamivudine (2 of them combined with adefovir). All 47 people were HBeAg-negative when they stopped therapy, and 46 had undetectable HBV DNA. Liver stiffness ranged from 3.3 to 6.6 kPa (median 5.2 kPa).
Six of these 47 people (13%) had to restart NUC therapy because of virologic flare (defined as HBV DNA above 2000 IU/mL) and/or biochemical flare (defined as alanine aminotransferase [ALT] more than 2 times the upper limit of normal). When these 6 stopped therapy their qHBsAg levels stood at 205, 147, 74, 21, 5.4, and 2.3. At their virologic flare their HBV DNA ranged from 265 to 152 million IU/mL (median 4663 IU/mL), and at biochemical flare their ALTs were 208, 938, 1467, 139, 828, and 149 IU/L. Time to restarting NUCs ranged from 62 to 177 days.
Hepatic dysfunction developed in no one who stopped NUC therapy, and all suppressed HBV DNA when treatment resumed (all with TDF). Two variables distinguished the 6 people who had to restart NUC therapy from the 41 who did not: (1) HBeAg-negative at baseline: 2 (33%) who restarted versus 36 (88%) who did not (P = 0.01); (2) longer NUC duration: median 12.4 years in restarters versus 6.1 years in sustained responders (P = 0.01). Age, sex, ethnicity, fibrosis stage F0-F1, and NUC taken did not affect relapse risk. qHBsAg when stopping therapy did not correlate with relapse. So far, 1 person who stopped therapy has lost HBsAg.
The Calgary investigators think their findings suggest that NUC withdrawal “is feasible” in HBeAg-negative people with chronic HBV infection, minimal fibrosis, and low qHBsAg levels. But because ALT flares can be severe, people who stop NUCs need close monitoring.
References
1. Azhari H, Frolkis A, Shaheen AA, et al. Real world single center experience on the efficacy of stopping long term nucleos(t)ide analog therapy in patients with chronic hepatitis B. AASLD The Liver Meeting Digital Experience, November 13-16, 2020. Abstract 24.
2. Consolidation therapy “generally involves treatment for at least 12 months of persistently normal ALT levels and undetectable serum HBV DNA levels.” Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261-83. doi: 10.1002/hep.28156. https://www.aasld.org/sites/defa ... 2016-Hepatology.pdf作者: StephenW 时间: 2020-11-15 12:52
關於慢性乙型肝炎患者停止長期核苷酸類似療法療效的真實世界單中心經驗
如果HBeAg陰性和HBsAg低於100 IU / mL，則停止抗HBV NUC“可行”
AASLD肝臟會議數字體驗，2020年11月13日至16日
馬克·馬斯科利尼
在加拿大進行的一項回顧性單中心研究結果表明，對於慢性乙型肝炎病毒而言，終止核苷類藥物（NUCs）是可行的，並且對於HBeAg陰性且定量HBsAg（qHBsAg）低於100 IU / mL的人群來說通常是安全的[1 ]。停止NUC的47人中有6人（佔13％）由於病毒或生化爆發而不得不重啟。
這47人中有6人（佔13％）由於病毒性耀斑（定義為2000 IU / mL以上的HBV DNA）和/或生化耀斑（定義為丙氨酸氨基轉移酶[ALT]大於上限的2倍）而不得不重新開始NUC治療。正常）。當這6個患者停止治療時，其qHBsAg水平分別為205、147、74、21、5.4和2.3。在病毒學耀斑下，他們的HBV DNA範圍為265至1.52億IU / mL（中位數4663 IU / mL），在生化耀斑下，其ALT為208、938、1467、139、828和149 IU / L。重新啟動NUC的時間為62到177天。